New Efficacy Data Adds to Successful Phase 3 Clinical Trial Program Results for Single-Dose Oral Cholera Vaccine for Travelers' Market and People in the Developing World
REDWOOD CITY, Calif., Jul 01, 2014 (BUSINESS WIRE) -- PaxVax Inc., a specialty vaccine company with a commercial focus on travel and biodefense and a social mission to ensure global access to its vaccines, today announced positive efficacy results from the 90-day challenge studies of its single-dose oral cholera vaccine candidate, PXVX0200, which utilizes the same attenuated vaccine strain (CVD 103-HgR) previously approved and marketed in several countries under the brand name Orochol. Trial investigators compared the rate of diarrhea in participants vaccinated with PXVX0200 to the rate in participants who had received placebo.
Vaccine efficacy was evaluated by immunizing volunteer participants with an oral dose of the PXVX0200 vaccine or placebo and then subsequently exposing them to the cholera-causing agent (Vibrio cholerae O1 El Tor). Volunteer participants in this challenge study were divided into two groups – the first group was vaccinated and then challenged at 10 days after vaccination, and a second, separate group of volunteer participants was challenged at 90 days post vaccination to further evaluate duration of vaccine protection.
In an analysis of participants challenged at 90 days post vaccination with wild type, fully pathogenic cholera bacteria, the efficacy rate was 79.5 percent – four of 33 participants who received PXVX0200 experienced moderate-to-severe diarrhea compared to 39 of 66 participants who received placebo. In the 10-day study group, post vaccination with wild type, fully pathogenic cholera bacteria, the efficacy rate was 90.3 percent – two of 35 participants who received PXVX0200 experienced moderate-to-severe diarrhea compared to 39 of 66 participants who received placebo.
Study Investigator Beth Kirkpatrick, M.D., Professor of Medicine, Infectious Disease Medicine, Department of Medicine, University of Vermont commented: "The 90-day challenge results are very encouraging and provide important new data that further support the efficacy of PXVX0200 in protecting people exposed to cholera. If approved, PXVX0200 has the potential to provide an effective new single-dose option for people living in and travelling to areas where cholera is endemic."
In addition to the 10- and 90-day cholera challenge studies, immunogenicity, safety, and lot-to-lot consistency of the PXVX0200 cholera vaccine are being evaluated in a broader population at study sites in Australia, Canada, and the U.S. Approximately 3,000 participants are being enrolled in these additional pivotal Phase 3 clinical studies.
"These favorable data build on a successful 10-day challenge study and provide important new data to support a Biologics License Application for PXVX0200, our lead commercial vaccine candidate," said Kenneth Kelley, Chief Executive Officer of PaxVax. "U.S. travelers currently have limited options to protect themselves from cholera, and we are pleased with the progress we are making in bringing an effective and logistically simple, single-dose cholera vaccine to travelers as well as developing countries for use during fast-moving cholera outbreaks."
Cholera is an acute intestinal diarrheal infection caused by toxigenic Vibrio cholerae bacteria generally acquired by ingesting contaminated water or food. According to the World Health Organization, the global disease burden is estimated to be three to five million cases and 100,000 to 130,000 deaths per year. Cholera often manifests as explosive epidemics that rapidly move through populations, such as the outbreaks that occurred in Peru and Haiti in 1991 and 2010, respectively.
A vaccine for cholera is not currently available for U.S. residents who travel abroad to areas where cholera poses a risk, such as Haiti or Central Africa. A cholera vaccine is available in Europe and elsewhere for travelers, but it requires a two-dose regimen. If licensed, the single-dose, oral PXVX0200 vaccine would be more convenient for all travelers, particularly for those traveling on short notice.
The 10- and 90-day challenge efficacy studies were randomized, double-blind, and placebo-controlled trials conducted at three top vaccine testing centers: the Center for Vaccine Development of the University of Maryland School of Medicine, the University of Vermont Vaccine Testing Center, and Cincinnati Children's Hospital Medical Center.
About PaxVax
Founded in 2007, PaxVax is a specialty vaccine company focused on developing effective vaccines for travel and biodefense. The company's clinical-stage portfolio includes its lead product, an oral, single-dose cholera vaccine in Phase 3 clinical trials, as well as vaccine candidates for H5N1 influenza and anthrax, which are currently in Phase 1 clinical trials. The company also has a pipeline of early-stage travel vaccine candidates for dengue, malaria and rabies. PaxVax is headquartered in Redwood City, California and has research and development laboratories and a state-licensed Good Manufacturing Practice (GMP) facility in San Diego, California. More information about PaxVax is available at www.PaxVax.com .
SOURCE: PaxVax Inc.
For PaxVax Inc.
Investor Contact:
Linda Rubinstein, EVP & CFO
+1.650.683.4146
or
Media Contact:
Maurissa Messier
+1.760.659.6700
Copyright Business Wire 2014